Allogene says lymphodepletion drug caused patient death, changes CAR-T study design

Allogene Therapeutics reported that a patient in its pivotal off-the-shelf CAR-T trial died from liver failure after receiving an experimental lymphodepletion drug. The patient’s death occurred nearly two months after they received the CAR-T therapy ...